• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.

作者信息

Enßle Julius C, Campe Julia, Schwenger Amelie, Wiercinska Eliza, Hellstern Helen, Dürrwald Ralf, Rieger Michael A, Wolf Sebastian, Ballo Olivier, Steffen Björn, Serve Hubert, Bonig Halvard, Rabenau Holger F, Widera Marek, Ciesek Sandra, Metzler Ivana von, Ullrich Evelyn

机构信息

Department of Medicine, Hematology/Oncology, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.

Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany.

出版信息

Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.

DOI:10.1182/blood.2021013429
PMID:34657156
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8734828/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f96/8734828/7f31caa66e1e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f96/8734828/488cbee42a5f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f96/8734828/7f31caa66e1e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f96/8734828/488cbee42a5f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f96/8734828/7f31caa66e1e/gr2_lrg.jpg

相似文献

1
Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma.多发性骨髓瘤患者对BNT162b2免疫接种的T细胞反应严重受损。
Blood. 2022 Jan 6;139(1):137-142. doi: 10.1182/blood.2021013429.
2
Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma.抗CD38疗法会损害多发性骨髓瘤患者针对新冠病毒α和δ变体的疫苗反应。
Blood. 2022 Feb 10;139(6):942-946. doi: 10.1182/blood.2021013714.
3
Attenuated humoral immune response following anti-SARS-CoV-2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis.在接受过大量治疗的多发性骨髓瘤和AL淀粉样变性患者中，抗SARS-CoV-2疫苗接种后体液免疫反应减弱。
Am J Hematol. 2021 Dec 1;96(12):E475-E478. doi: 10.1002/ajh.26373. Epub 2021 Oct 16.
4
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma.接种过疫苗的多发性骨髓瘤患者感染新型冠状病毒2型（SARS-CoV-2）的情况。
Blood Cancer J. 2021 Dec 14;11(12):201. doi: 10.1038/s41408-021-00597-y.
5
Booster BNT162b2 optimizes SARS-CoV-2 humoral response in patients with myeloma: the negative effect of anti-BCMA therapy.加强接种BNT162b2优化骨髓瘤患者的SARS-CoV-2体液反应：抗BCMA疗法的负面影响。
Blood. 2022 Mar 3;139(9):1409-1412. doi: 10.1182/blood.2021014989.
6
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients.造血干细胞移植患者接种BNT162b2抗SARS-CoV-2 mRNA疫苗后的血清学反应。
Br J Haematol. 2022 Feb;196(4):928-931. doi: 10.1111/bjh.17873. Epub 2021 Oct 18.
7
Myeloma patients with COVID-19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine.与完全接种 BNT162b2 疫苗的患者相比，感染 COVID-19 的骨髓瘤患者具有更高的抗体反应。
Br J Haematol. 2022 Jan;196(2):356-359. doi: 10.1111/bjh.17841. Epub 2021 Sep 16.
8
Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.异源 ChAdOx1 nCoV-19 和 BNT162b2 疫苗加强接种可引发针对流行的 SARS-CoV-2 变体的强大中和抗体反应和 T 细胞反应性。
EBioMedicine. 2022 Jan;75:103761. doi: 10.1016/j.ebiom.2021.103761. Epub 2021 Dec 17.
9
Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.第三剂 BNT162b2 疫苗可诱导先前无反应的老年人群产生针对 SARS-CoV-2 的强大细胞和体液免疫。
Nat Microbiol. 2022 Feb;7(2):195-199. doi: 10.1038/s41564-021-01046-z. Epub 2022 Jan 10.
10
Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.在患有淋巴恶性肿瘤的患者中，第三剂 SARS-CoV-2 BNT162b2 疫苗后的体液和细胞反应。
Nat Commun. 2022 Feb 14;13(1):864. doi: 10.1038/s41467-022-28578-0.

引用本文的文献

1
Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma.多发性骨髓瘤患者接种一剂与两剂甲型/乙型流感疫苗后的免疫反应。
Ann Hematol. 2025 May;104(5):2813-2821. doi: 10.1007/s00277-025-06367-1. Epub 2025 May 15.
2
Patients with multiple myeloma infected with COVID-19 during autologous stem cell transplantation.在自体干细胞移植期间感染新冠病毒的多发性骨髓瘤患者。
Infect Agent Cancer. 2024 Aug 12;19(1):38. doi: 10.1186/s13027-024-00603-5.
3
Breakthrough Infections in SARS-CoV-2-Vaccinated Multiple Myeloma Patients Improve Cross-Protection against Omicron Variants.

本文引用的文献

1
Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.更正：纽约市多发性骨髓瘤患者的新冠病毒感染及转归：一项来自五个学术中心的队列研究。
Blood Cancer Discov. 2020 Nov 4;1(3):290. doi: 10.1158/2643-3230.BCD-20-0160. eCollection 2020 Nov.
2
COVID-19 in multiple-myeloma patients: cellular and humoral immunity against SARS-CoV-2 in a short- and long-term view.COVID-19 与多发性骨髓瘤：从短期和长期来看多发性骨髓瘤患者对 SARS-CoV-2 的细胞和体液免疫。
J Mol Med (Berl). 2022 Mar;100(3):463-470. doi: 10.1007/s00109-021-02114-x. Epub 2021 Oct 18.
3
接种SARS-CoV-2疫苗的多发性骨髓瘤患者中的突破性感染改善了对奥密克戎变种的交叉保护。
Vaccines (Basel). 2024 May 9;12(5):518. doi: 10.3390/vaccines12050518.
4
Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis.系统评价和荟萃分析：多发性骨髓瘤患者对 COVID-19 疫苗接种的免疫反应。
BMC Geriatr. 2024 May 8;24(1):411. doi: 10.1186/s12877-024-05006-0.
5
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.细胞因子反应性 T 细胞和 NK 细胞描绘了多发性骨髓瘤患者对 SARS-CoV-2 疫苗的反应和感染情况。
Leukemia. 2024 Jan;38(1):168-180. doi: 10.1038/s41375-023-02070-0. Epub 2023 Dec 4.
6
Humoral and cellular responses to SARS-CoV-2 in patients with B-cell haematological malignancies improve with successive vaccination.B 细胞血液恶性肿瘤患者对 SARS-CoV-2 的体液和细胞反应随着连续接种疫苗而改善。
Br J Haematol. 2023 Sep;202(6):1091-1103. doi: 10.1111/bjh.18962. Epub 2023 Jul 4.
7
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma.活动性多发性骨髓瘤患者对SARS-CoV-2 mRNA疫苗的体液和细胞反应的长期随访
Front Oncol. 2023 May 25;13:1208741. doi: 10.3389/fonc.2023.1208741. eCollection 2023.
8
Impact of novel agent therapies on immune cell subsets and infectious complications in patients with relapsed/refractory multiple myeloma.新型药物疗法对复发/难治性多发性骨髓瘤患者免疫细胞亚群及感染并发症的影响
Front Oncol. 2023 Apr 21;13:1078725. doi: 10.3389/fonc.2023.1078725. eCollection 2023.
9
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN).《后疫情时代多发性骨髓瘤合并 COVID-19 患者的管理：来自欧洲骨髓瘤网络（EMN）的共识文件》。
Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1. Epub 2023 May 4.
10
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia.浆细胞疾病患者对第二和第三次严重急性呼吸综合征冠状病毒 2 mRNA 疫苗的体液和细胞免疫反应。
Cancer Med. 2023 Jun;12(12):13135-13144. doi: 10.1002/cam4.5996. Epub 2023 Apr 26.
Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer.
当前提高正在接受癌症积极治疗的患者对 SARS-CoV-2 疫苗效力的观点。
Eur J Cancer. 2021 Sep;154:66-72. doi: 10.1016/j.ejca.2021.06.008. Epub 2021 Jun 18.
4
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.多发性骨髓瘤患者对两剂新冠病毒RNA疫苗的严重急性呼吸综合征冠状病毒2刺突抗体反应高度可变。
Cancer Cell. 2021 Aug 9;39(8):1028-1030. doi: 10.1016/j.ccell.2021.06.014. Epub 2021 Jun 29.
5
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.立陶宛血液系统恶性肿瘤患者的 BNT162b2 COVID-19 mRNA 疫苗免疫原性和早期临床结局：一项全国前瞻性队列研究。
Lancet Haematol. 2021 Aug;8(8):e583-e592. doi: 10.1016/S2352-3026(21)00169-1. Epub 2021 Jul 2.
6
Seroconversion rates following COVID-19 vaccination among patients with cancer.癌症患者接种 COVID-19 疫苗后的血清转化率。
Cancer Cell. 2021 Aug 9;39(8):1081-1090.e2. doi: 10.1016/j.ccell.2021.06.002. Epub 2021 Jun 5.
7
Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.不同替代酶联免疫吸附测定法（sELISA）检测新型冠状病毒2（SARS-CoV-2）中和抗体的效用
J Clin Med. 2021 May 14;10(10):2128. doi: 10.3390/jcm10102128.
8
CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer.CD8 T 细胞有助于 COVID-19 和血液系统癌症患者的存活。
Nat Med. 2021 Jul;27(7):1280-1289. doi: 10.1038/s41591-021-01386-7. Epub 2021 May 20.
9
Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer.癌症患者对 SARS-CoV-2 的预先存在和 COVID-19 后免疫反应。
Cancer Discov. 2021 Aug;11(8):1982-1995. doi: 10.1158/2159-8290.CD-21-0191. Epub 2021 May 19.
10
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.中和抗体水平高度预测对有症状的 SARS-CoV-2 感染的免疫保护作用。
Nat Med. 2021 Jul;27(7):1205-1211. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.